View Clinical Trial (Medical Research Study)
Effect of Whole Body Periodic Acceleration on Airway Endothelial Function in Healthy Smokers, Non-smokers and Asmathics
| City: |
|
Miami |
| State: |
|
Florida |
| Zip Code: |
|
33136 |
| Conditions: |
|
Healthy Control - Smokers - Asthma |
| Purpose: |
|
In the present proposal the investigators wish to assess the effect of a single session with
the device known as Exer-Rest® which applies Whole Body Periodic Acceleration (WBPA) on
baseline airway blood flow (Qaw) and in Qaw variation, in current smokers,
glucocorticoid-naïve asthmatics, and age-matched healthy never-smokers, with the expectation
that the treatment will transiently increase the Qaw, and to a greater extent in the current
smokers and patients with asthma who have endothelial dysfunction.
|
| Study Summary: |
|
Endothelial shear stress activates nitric oxide synthase (NOS), leading to
endothelium-dependent vasodilation. This can be accomplished through exercise or with a
device known as Exer-Rest® which applies Whole Body Periodic Acceleration (WBPA) that is
also called pGz. WBPA produces systemic vasodilation, by exerting shear stress on the
vascular endothelium, activating endothelial NOS and releasing NO in animal models and human
subjects. Cigarette smoking is associated with attenuated vascular relaxation responses in
the systemic circulation. Patients with asthma also exhibit endothelial dysfunction in the
airway. In this study the investigators wish to assess the effect of a single pGz session on
baseline Qaw and delta Qaw in current smokers, glucocorticoid-naïve asthmatics, and
age-matched healthy never-smokers to test if this treatment will increase the vascular
relaxation responses.
|
| Criteria: |
|
Inclusion Criteria:
15 healthy never-smokers, 15 smokers (> than 1 year smoke history) and 15 never-smokers
asmathics; FEV1 > 80% (except for asmathics subjets)
Exclusion Criteria:
Women of childbearing potential who do not accepted birth control measures; pregnant and
breast feeding; cardiovascular disease or use of cardiovascular drugs; respiratory
infection during the 4 weeks preceding the study; use of inhaled or systemic
glucocorticoids, leukotriene modifiers or theophyllines in asmathics; FEV1 < 80% on the
screening day (excepted for asmathics subjets)
|
| NCT ID: |
|
NCT01213706 |
| Primary Contact: |
|
Principal Investigator
Adam Wanner, MD
University of Miami
Adam Wanner, MD
Phone: (305) 243-2568
Email: awanner@miami.edu
|
| Backup Contact: |
|
Email: emendes@med.miami.edu
Eliana Mendes, MD
Phone: (305) 243-2568
|
| Location Contact: |
|
Miami, Florida 33136
United States
Adam Wanner, MD
Phone: 305-243-2568
Email: awanner@miami.edu
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
June 18, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|